FEB 11, 2016 3:22 PM PST

Treating TTP with Synthetic Antibodies

WRITTEN BY: Kara Marker
Rare but deadly, thrombotic thrombocytopenic purpura (TTP) is a disease where blood clots block the smallest blood vessels often leading to kidney failure, stroke, and heart disease. Over 4 million Americans are affected each year, either from hereditary or acquired forms of the disease.
 
Past the acute phase, TTP is relatively easily defeated with immunotherapy, said Paul Knöbl from the Medical University of Vienna. However, 10 to 20 percent of people do not survive the acute phase, even with plasma exchange therapy. In a new study published in the New England Journal of Medicine, Knöbl and other researchers from the Medical University of Vienna examined the capability of a synthesized antibody to reverse the impact of the disease.
 
Newly formed blood vessel within an occluded artery of the lower leg

 
TTP is characterized by a deficiency of an enzyme called ADAMST13 regardless of whether the disease was acquired or inherited. Without ADAMST13, another protein called von Willebrand is overexpressed and destructively so, binding platelets and inducing aggregation in blood vessels. Blood clots caused by TTP can lead to kidney failure, stroke, and heart disease.
 
Current plasma exchange therapy removes autoantibodies causing the ADAMST13 deficiency, removes overgrown von Willebrand protein complexes, and replenishes the body’s stock of ADAMST13. After a patient survives the acute phase, immunotherapy prevents continuous autoantibody formation. The synthesized antibody proposed by this study would be used for treatment both during and after the acute phase, instead targeting the masses of overactive von Willebrand protein. By blocking the protein’s interaction with platelets, the antibody reduces the severity of blood clots characterizing TTP to practically zero.
 
"In future this drug might also be used to treat similar diseases, which are jointly caused by overactivity of the von Willebrand factor, and therefore represents a new treatment option," said the Medical University of Vienna’s Bernd Jilma.
 
The antibody being studied is called “caplacizumab.”
 

Source: Medical University of Vienna, New England Journal of Medicine
 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
JUL 12, 2019
Cardiology
JUL 12, 2019
Many Cardiac Interventions Not Proven Beneficial
Doctors have recommended numerous interventions to combat heart disease. With heart disease killing more people in the United States than anything else, th...
JUL 13, 2019
Cardiology
JUL 13, 2019
Those With Views Of Nature From Their Homes, Healthier
The benefits of exposing yourself to nature are well documented. Our proximity to nature influences everything from mental-health to air quality. Studies h...
JUL 23, 2019
Cardiology
JUL 23, 2019
Shocking Numbers Of People Self-Prescribing Daily Aspirin
Up until recently, people who were concerned about the possibility of suffering a cardiac event were often advised to take low-dose aspirin daily. Because ...
AUG 08, 2019
Cardiology
AUG 08, 2019
No Increase In Risk For Home Births
Most babies in the United States are born in hospitals. That said, the number of mothers electing to give birth at home is on the rise. This trend lik...
SEP 06, 2019
Cardiology
SEP 06, 2019
Poor U.S. Counties Have More Heart Failure Deaths
In 2009, one in nine U.S. deaths included heart failure as contributing cause, according to the Centers for Disease Control (CDC). And about half of the pe...
OCT 25, 2019
Cardiology
OCT 25, 2019
Cardiac Mapping for Arrhythmia Diagnosis
Cardiac mapping is an essential diagnostic tool. These imagining tools are used for diagnosing arrhythmias in the heart. Cardiac mapping can be done in sev...
Loading Comments...